BioCentury
ARTICLE | Company News

moksha8, Forest Laboratories deal

January 13, 2014 8:00 AM UTC

Forest no longer has an option to acquire moksha8 for $157 million. Forest gained the option under a 2012 deal in which the company granted moksha8 exclusive commercialization rights in Latin America to Forest's antidepressant Viibryd vilazodone and potentially other Forest products. Forest also will no longer be obligated to provide moksha8 financing. Under the original deal, Forest agreed to provide moksha8 $125 million in financing over a two-year period. As of Nov. 1, moksha8 had received $101.9 million from Forest. moksha8 declined to disclose details, and Forest did not respond in time for publication (see BioCentury, Oct. 29, 2012). ...